MXPA04006553A - Compuesto de 4-oxoquinolina y uso del mismo como inhibidor de integrasa de vih. - Google Patents

Compuesto de 4-oxoquinolina y uso del mismo como inhibidor de integrasa de vih.

Info

Publication number
MXPA04006553A
MXPA04006553A MXPA04006553A MXPA04006553A MXPA04006553A MX PA04006553 A MXPA04006553 A MX PA04006553A MX PA04006553 A MXPA04006553 A MX PA04006553A MX PA04006553 A MXPA04006553 A MX PA04006553A MX PA04006553 A MXPA04006553 A MX PA04006553A
Authority
MX
Mexico
Prior art keywords
hiv
hiv agent
integrase
inhibitor
agent
Prior art date
Application number
MXPA04006553A
Other languages
English (en)
Spanish (es)
Inventor
Shuichi Wamaki
Original Assignee
Japan Tobacco Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32329647&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MXPA04006553(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Japan Tobacco Inc filed Critical Japan Tobacco Inc
Publication of MXPA04006553A publication Critical patent/MXPA04006553A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/58—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems with hetero atoms directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
MXPA04006553A 2002-11-20 2004-07-02 Compuesto de 4-oxoquinolina y uso del mismo como inhibidor de integrasa de vih. MXPA04006553A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2002336843 2002-11-20
JP2003065807 2003-03-11
JP2003139616 2003-05-16

Publications (1)

Publication Number Publication Date
MXPA04006553A true MXPA04006553A (es) 2004-10-04

Family

ID=32329647

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA04006553A MXPA04006553A (es) 2002-11-20 2004-07-02 Compuesto de 4-oxoquinolina y uso del mismo como inhibidor de integrasa de vih.

Country Status (31)

Country Link
US (6) US7176220B2 (OSRAM)
EP (5) EP2272516A3 (OSRAM)
KR (1) KR100665919B1 (OSRAM)
AR (2) AR042095A1 (OSRAM)
AT (1) ATE443048T1 (OSRAM)
AU (1) AU2003302029B8 (OSRAM)
BE (1) BE2013C063I2 (OSRAM)
BR (1) BRPI0306214B1 (OSRAM)
CA (1) CA2470365C (OSRAM)
CY (2) CY1110690T1 (OSRAM)
CZ (1) CZ2004764A3 (OSRAM)
DE (1) DE60329318D1 (OSRAM)
DK (1) DK1564210T5 (OSRAM)
ES (1) ES2329240T3 (OSRAM)
FR (1) FR13C0061I2 (OSRAM)
HU (1) HUS1300066I1 (OSRAM)
IL (2) IL162548A0 (OSRAM)
LT (1) LTPA2013018I1 (OSRAM)
LU (1) LU92307I2 (OSRAM)
MX (1) MXPA04006553A (OSRAM)
MY (1) MY136173A (OSRAM)
NO (3) NO327098B1 (OSRAM)
NZ (1) NZ533641A (OSRAM)
PE (1) PE20040840A1 (OSRAM)
PT (1) PT1564210E (OSRAM)
SI (1) SI1564210T1 (OSRAM)
SK (1) SK2662004A3 (OSRAM)
TR (1) TR200401663T1 (OSRAM)
TW (1) TWI248928B (OSRAM)
WO (1) WO2004046115A1 (OSRAM)
ZA (1) ZA200404537B (OSRAM)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1441735T3 (da) 2001-10-26 2006-06-12 Angeletti P Ist Richerche Bio N-substituerede hydroxypyrimidinon-carboxamid-inhibitorer af HIV-integrase
SI1564210T1 (sl) * 2002-11-20 2010-01-29 Japan Tobacco Inc 4-oksokinolinske spojine in njihova uporaba kot inhibitorji HIV integraze
ATE482208T1 (de) 2004-03-10 2010-10-15 Us Of America Represented By T Chinolin-4-one als inhibitoren der retroviralen integrase zur behandlung von hiv, aids und aids- related complex (arc)
MY134672A (en) * 2004-05-20 2007-12-31 Japan Tobacco Inc Stable crystal of 4-oxoquinoline compound
US7531554B2 (en) 2004-05-20 2009-05-12 Japan Tobacco Inc. 4-oxoquinoline compound and use thereof as HIV integrase inhibitor
EP2332538A1 (en) * 2004-05-21 2011-06-15 Japan Tobacco, Inc. Combinations comprising a 4-isoquinolone derivative and anti-HIV agents
WO2006033422A1 (ja) * 2004-09-21 2006-03-30 Japan Tobacco Inc. キノリジノン化合物、およびそのｈｉｖインテグラーゼ阻害剤としての利用
US7745459B2 (en) * 2004-09-21 2010-06-29 Japan Tobacco Inc. Quinolizinone compound and use thereof as HIV integrase inhibitor
UA87884C2 (uk) * 2004-12-03 2009-08-25 Мерк Энд Ко., Инк. Безводна кристалічна калієва сіль інгібітора віл-інтегрази
US7772191B2 (en) 2005-05-10 2010-08-10 Boehringer Ingelheim International Gmbh Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein
US20070032522A1 (en) * 2005-07-01 2007-02-08 Kumar Dange V Antiviral agents
WO2007063869A1 (ja) * 2005-11-30 2007-06-07 Japan Tobacco Inc. 高純度キノロン化合物の製造方法
AU2013203476C1 (en) * 2005-12-30 2016-11-17 Gilead Sciences, Inc. Methods for improving the pharmacokinetics of hiv integrase inhibitors
SG170795A1 (en) * 2005-12-30 2011-05-30 Gilead Sciences Inc Methods for improving the pharmacokinetics of hiv integrase inhibitors
US20090233964A1 (en) * 2005-12-30 2009-09-17 Gilead Sciences, Inc. Methods for improving the pharmacokinetics of hiv integrase inhibitors
US20090018162A1 (en) * 2006-02-01 2009-01-15 Yuji Matsuzaki Use of 6-(3-chloro-2-fluorobenzyl)-1-[(2s)-1-hydroxy-3-methylbutan-2-yl]-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid or salt thereof for treating retrovirus infection
WO2007092802A1 (en) * 2006-02-09 2007-08-16 Boehringer Ingelheim International Gmbh Method for treating hiv infection through co-administration of tipranavir and gs 9137
BRPI0708685B8 (pt) 2006-03-06 2021-05-25 Japan Tobacco Inc composto de 4-oxoquinolina, seu uso e método para produção dos mesmos
WO2007102499A1 (ja) * 2006-03-06 2007-09-13 Japan Tobacco Inc. ４－オキソキノリン化合物の製造方法
PE20080697A1 (es) 2006-05-03 2008-08-05 Boehringer Ingelheim Int Derivados de benzonitrilo sustituidos con glucopiranosilo, composiciones farmaceuticas que contienen compuestos de este tipo, su uso y procedimiento para su fabricacion
TW200811153A (en) * 2006-06-23 2008-03-01 Japan Tobacco Inc 6-(heterocyclyl-substituted benzyl)-4-oxoquinoline compound and use thereof as HIV integrase inhibitor
RU2399616C1 (ru) * 2006-06-23 2010-09-20 Джапан Тобакко Инк. Производное 6-(гетероциклзамещенный бензил)-4-оксохинолина и его применение в качестве ингибитора интегразы вич
AP2985A (en) 2006-07-07 2014-09-30 Gilead Sciences Inc Modulators of pharmacokinetic properties of therapeutics
AU2007275805A1 (en) 2006-07-19 2008-01-24 University Of Georgia Research Foundation, Inc. Pyridinone diketo acids: Inhibitors of HIV replication in combination therapy
CA2661943C (en) 2006-09-12 2015-11-03 Gilead Sciences, Inc. Process and intermediates for preparing integrase inhibitors
BRPI0717511A2 (pt) 2006-09-29 2013-11-19 Idenix Pharmaceuticals Inc Composto puro, composição farmacêutica, métodos para tratar uma infecção por hiv, para prevenir uma infecção por hiv, para inibir a replicação de hiv, e, uso de um composto
EP2269992A1 (en) 2006-12-22 2011-01-05 Avexa Limited Bicyclic pyrimidinones for the treatment of viral infections
LT2487163T (lt) * 2007-02-23 2016-10-25 Gilead Sciences, Inc. Terapinių agentų farmakokinetinių savybių moduliatoriai
JP5547067B2 (ja) * 2007-06-29 2014-07-09 ギリアード サイエンシーズ， インコーポレイテッド 治療組成物およびその使用
EP2167088A1 (en) * 2007-06-29 2010-03-31 Gilead Sciences, Inc. Therapeutic compositions and the use thereof
PE20090938A1 (es) 2007-08-16 2009-08-08 Boehringer Ingelheim Int Composicion farmaceutica que comprende un derivado de benceno sustituido con glucopiranosilo
AR068403A1 (es) * 2007-09-11 2009-11-18 Gilead Sciences Inc Proceso e intermediarios para la preparacion de inhibidores de integrasa
US7994194B2 (en) * 2007-09-12 2011-08-09 Concert Pharmaceuticals, Inc. 4-oxoquinoline derivatives
US8377960B2 (en) * 2007-11-15 2013-02-19 Gilead Sciences, Inc. Inhibitors of human immunodeficiency virus replication
NZ585226A (en) 2007-11-16 2012-08-31 Gilead Sciences Inc Inhibitors of human immunodeficiency virus replication
EP2543368A1 (en) 2007-12-11 2013-01-09 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitors using metal binding moieties in combination with targeting moieties
CA2711500A1 (en) * 2008-01-07 2009-07-16 Huanming Chen Novel hiv integrase inhibitors and methods of use
BRPI0911871A8 (pt) 2008-05-02 2018-03-06 Gilead Sciences Inc uso de partículas veículo sólidas para melhorar a processabilidade de um agente farmacêutico
WO2010073078A2 (en) * 2008-12-22 2010-07-01 Orchid Research Laboratories Ltd. Heterocyclic compounds as hdac inhibitors
HRP20151009T1 (hr) 2009-02-06 2015-10-23 Gilead Sciences, Inc. Dvoslojna tableta koja sadrži elvitegravir, kobicistat, emtricitabin i tenofovir
LT2395983T (lt) 2009-02-13 2020-07-10 Boehringer Ingelheim International Gmbh Farmacinė kompozicija, apimanti sglt2 inhibitorių, dpp-iv inhibitorių ir, pasirinktinai, papildomą priešdiabetinį agentą, bei jos panaudojimas
WO2010137032A2 (en) 2009-05-14 2010-12-02 Matrix Laboratories Ltd. Novel polymorphic forms of elvitegravir and its pharmaceutically acceptable salts
WO2011004389A2 (en) 2009-06-18 2011-01-13 Matrix Laboratories Ltd An improved process for the preparation of elvitegravir
WO2011025683A1 (en) * 2009-08-26 2011-03-03 Merck Sharp & Dohme Corp. Hiv integrase inhibitors
WO2011039108A2 (en) 2009-09-30 2011-04-07 Boehringer Ingelheim International Gmbh Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives
PH12012500633B1 (en) 2009-09-30 2017-12-13 Boehringer Ingelheim Int Method for the preparation of a crystalline form of 1-chloro -4- (beta -d- glucopyranos -1-yl) -2- (4-((s)- tetrahydrofuran -3- yloxy) benzyl) benzene
UY32919A (es) 2009-10-02 2011-04-29 Boehringer Ingelheim Int Composición farmacéutica, forma de dosificación farmacéutica, procedimiento para su preparación, mé todos para su tratamiento y sus usos
AU2010305805B2 (en) 2009-10-13 2014-04-03 Elanco Animal Health Ireland Limited Macrocyclic integrase inhibitors
EA201270651A1 (ru) 2009-12-07 2013-01-30 Юниверсити Оф Джорджия Рисерч Фаундейшн, Инк. Карбоксамиды пиридинон гидроксициклопентила: ингибиторы вич интегразы и области терапевтического применения
JP5739517B2 (ja) 2010-04-02 2015-06-24 ヤンセン・アールアンドデイ・アイルランド 大環状インテグラーゼ阻害剤
DE102010021637A1 (de) 2010-05-26 2011-12-01 Bayer Schering Pharma Aktiengesellschaft Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung
PH12013500011A1 (en) 2010-07-02 2013-02-18 Gilead Sciences Inc Napht-2-ylacetic acid derivatives to treat aids
NZ604716A (en) 2010-07-02 2014-12-24 Gilead Sciences Inc 2-quinolinyl-acetic acid derivatives as hiv antiviral compounds
UY33937A (es) 2011-03-07 2012-09-28 Boehringer Ingelheim Int Composiciones farmacéuticas que contienen inhibidores de dpp-4 y/o sglt-2 y metformina
JP5918848B2 (ja) 2011-04-21 2016-05-18 ギリアード サイエンシーズ， インコーポレイテッド ベンゾチアゾール化合物およびその薬学的使用
US9376392B2 (en) 2012-01-04 2016-06-28 Gilead Sciences, Inc. 2-(tert-butoxy)-2-(7-methylquinolin-6-yl) acetic acid derivatives for treating AIDS
US9284323B2 (en) 2012-01-04 2016-03-15 Gilead Sciences, Inc. Naphthalene acetic acid derivatives against HIV infection
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
US9192617B2 (en) 2012-03-20 2015-11-24 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
US8987250B2 (en) 2012-04-20 2015-03-24 Gilead Sciences, Inc. Therapeutic compounds
EA026089B1 (ru) * 2012-08-03 2017-02-28 Джилид Сайэнс, Инк. Способ и промежуточные соединения для получения ингибиторов интегразы
CZ304983B6 (cs) 2012-10-12 2015-03-11 Zentiva, K.S. Způsob výroby a nové intermediáty syntézy elvitegraviru
CZ304984B6 (cs) 2012-10-12 2015-03-11 Zentiva, K.S. Zlepšený způsob výroby a nové intermediáty syntézy elvitegraviru
AU2013361401C1 (en) 2012-12-21 2018-08-09 Gilead Sciences, Inc. Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
MX381156B (es) 2012-12-26 2025-03-12 Soc Des Produits Nestle S A Star Composiciones de arena para animales recubiertas de baja densidad.
HK1213818A1 (zh) 2013-04-05 2016-07-15 勃林格殷格翰国际有限公司 依帕列净的治疗用途
CA2812519A1 (en) 2013-04-05 2014-10-05 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
PT2981271T (pt) 2013-04-05 2019-02-19 Boehringer Ingelheim Int Utilizações terapêuticas de empagliflozina
US11813275B2 (en) 2013-04-05 2023-11-14 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
EA033286B1 (ru) 2013-04-18 2019-09-30 Бёрингер Ингельхайм Интернациональ Гмбх Способ лечения или отсрочки развития хронической болезни почек
CZ307255B6 (cs) 2013-07-11 2018-05-02 Zentiva, K.S. Nový způsob přípravy elvitegraviru
NO2865735T3 (OSRAM) 2013-07-12 2018-07-21
PL3019503T3 (pl) 2013-07-12 2018-01-31 Gilead Sciences Inc Policykliczne związki karbamoilopirydonowe i ich zastosowanie do leczenia infekcji hiv
TWI677489B (zh) 2014-06-20 2019-11-21 美商基利科學股份有限公司 多環型胺甲醯基吡啶酮化合物之合成
NO2717902T3 (OSRAM) 2014-06-20 2018-06-23
TW201613936A (en) 2014-06-20 2016-04-16 Gilead Sciences Inc Crystalline forms of(2R,5S,13aR)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide
JP2017538689A (ja) * 2014-11-17 2017-12-28 ニーロジョン セラピューティクス インコーポレイテッドＮｉｒｏｇｙｏｎｅ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． モノカルボン酸輸送修飾薬およびその使用
TWI738321B (zh) 2014-12-23 2021-09-01 美商基利科學股份有限公司 多環胺甲醯基吡啶酮化合物及其醫藥用途
CN110790773A (zh) 2015-04-02 2020-02-14 吉利德科学公司 多环氨甲酰基吡啶酮化合物及其药物用途
WO2016193997A2 (en) * 2015-06-03 2016-12-08 Msn Laboratories Private Limited Process for the preparation of 6-(3-chloro-2-fluorobenzyl)-1-[(2s)-1-hydroxy-3-methylbutan-2-yl]-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid and pharmaceutically acceptable salts thereof
ES2926334T3 (es) 2015-10-23 2022-10-25 Nestle Sa Arenas higiénicas para mascotas de baja densidad y métodos de elaboración y uso de tales arenas higiénicas para mascotas
RU2654062C2 (ru) * 2016-07-14 2018-05-16 Государственное бюджетное образовательное учреждение высшего профессионального образования "Волгоградский государственный медицинский университет" Министерства здравоохранения Российской Федерации Производные хиназолин-4(3н)-она, ингибирующие натрий-водородный обмен
JP7625363B2 (ja) 2016-11-10 2025-02-03 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 医薬組成物、治療方法及びその使用

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3472859A (en) * 1966-11-01 1969-10-14 Sterling Drug Inc 1-alkyl-1,4-dihydro-4-oxo-3 quinoline-carboxylic acids and esters
JPS4826772A (OSRAM) 1971-08-11 1973-04-09
DE3501247A1 (de) 1985-01-16 1986-07-17 Bayer Ag, 5090 Leverkusen Aminoacrylsaeure-derivate
US5591744A (en) * 1987-04-16 1997-01-07 Otsuka Pharmaceutical Company, Limited Benzoheterocyclic compounds
EP0319906A3 (en) * 1987-12-11 1990-05-02 Dainippon Pharmaceutical Co., Ltd. Novel quinoline derivatives, processes for preparation thereof and antibacterial agent containing them
US4920120A (en) * 1988-01-25 1990-04-24 Warner-Lambert Company Antibacterial agents
DE3934082A1 (de) * 1989-10-12 1991-04-18 Bayer Ag Chinoloncarbonsaeurederivate, verfahren zu ihrer herstellung sowie ihre verwendung als antivirale mittel
DE4015299A1 (de) 1990-05-12 1991-11-14 Bayer Ag Verfahren zur herstellung von 3-amino-2-(het)-aroyl-acrylsaeurederivaten
IL100555A (en) 1991-02-07 2000-08-31 Hoechst Marion Roussel Inc N-substituted quinoline derivatives their preparation their use for the preparation of medicaments and the pharmaceutical compositions containing them
NO304832B1 (no) 1992-05-27 1999-02-22 Ube Industries Aminokinolonderivater samt middel mot HIV
JP2993316B2 (ja) 1992-05-27 1999-12-20 宇部興産株式会社 アリール基又は複素芳香環基置換アミノキノロン誘導体及びエイズ治療剤
JPH06199635A (ja) 1992-12-28 1994-07-19 Kanebo Ltd 化粧料
JPH06199835A (ja) 1993-01-08 1994-07-19 Hokuriku Seiyaku Co Ltd ８−ジフルオロメトキシキノリン−３−カルボン酸誘導体
JPH06271568A (ja) 1993-03-22 1994-09-27 Hokuriku Seiyaku Co Ltd ７−フェニルピペラジニルキノリン−３−カルボン酸誘導体
WO1995029891A1 (en) 1994-04-28 1995-11-09 Yamanouchi Pharmaceutical Co., Ltd. N-(3-pyrrolidinyl)benzamide derivative
JP2930539B2 (ja) 1994-07-18 1999-08-03 三共株式会社 トリフルオロメチルキノリンカルボン酸誘導体
AU683569B2 (en) 1994-07-18 1997-11-13 Sankyo Company Limited Trifluoromethylquinolinecarboxylic acid derivative
JPH08183776A (ja) 1994-12-28 1996-07-16 Hideaki Yamaguchi 金属の表面保護剤ならびにそれを用いた製造方法
US6303611B1 (en) * 1996-03-08 2001-10-16 Adolor Corporation Kappa agonist compounds and pharmaceutical formulations thereof
JP4121151B2 (ja) * 1996-04-12 2008-07-23 アメリカ合衆国 抗新生物薬および抗レトロウイルス薬として有用なアクリドンから誘導された化合物
US6287550B1 (en) * 1996-12-17 2001-09-11 The Procter & Gamble Company Animal care system and litter with reduced malodor impression
US5989451A (en) 1997-02-07 1999-11-23 Queen's University At Kingston Compounds and methods for doping liquid crystal hosts
FR2761687B1 (fr) * 1997-04-08 2000-09-15 Centre Nat Rech Scient Derives de quinoleines, possedant notamment des proprietes antivirales, leurs preparations et leurs applications biologiques
JP3776203B2 (ja) 1997-05-13 2006-05-17 第一製薬株式会社 Ｉｃａｍ−１産生阻害剤
KR20010013377A (ko) * 1997-06-04 2001-02-26 데이비드 엠 모이어 마일드한 잔류성 항균 조성물
TW527355B (en) 1997-07-02 2003-04-11 Bristol Myers Squibb Co Inhibitors of farnesyl protein transferase
JPH1184556A (ja) 1997-09-08 1999-03-26 Konica Corp ハロゲン化銀乳剤、該乳剤を用いる感光材料の処理方法及び撮影方法
GB9721964D0 (en) 1997-10-16 1997-12-17 Pfizer Ltd Isoquinolines
GB9807903D0 (en) 1998-04-14 1998-06-10 Smithkline Beecham Plc Novel compounds
US6399629B1 (en) 1998-06-01 2002-06-04 Microcide Pharmaceuticals, Inc. Efflux pump inhibitors
US6248739B1 (en) 1999-01-08 2001-06-19 Pharmacia & Upjohn Company Quinolinecarboxamides as antiviral agents
US6248736B1 (en) 1999-01-08 2001-06-19 Pharmacia & Upjohn Company 4-oxo-1,4-dihydro-3-quinolinecarboxamides as antiviral agents
FR2795726A1 (fr) 1999-06-30 2001-01-05 Aventis Cropscience Sa Nouveaux pyrazoles fongicides
DE19950898A1 (de) * 1999-10-22 2001-04-26 Aventis Pharma Gmbh Heterocyclisch substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
PE20011349A1 (es) * 2000-06-16 2002-01-19 Upjohn Co 1-aril-4-oxo-1,4-dihidro-3-quinolincarboxamidas como agentes antivirales
US6559145B2 (en) 2000-07-12 2003-05-06 Pharmacia & Upjohn Company Heterocycle carboxamides as antiviral agents
US6730682B2 (en) 2000-07-12 2004-05-04 Pharmacia & Upjohn Company Heterocycle carboxamides as antiviral agents
CA2425625A1 (en) 2000-10-12 2002-07-18 Merck & Co., Inc. Aza-and polyaza-naphthalenyl carboxamides useful as hiv integrase inhibitors
US20050010048A1 (en) 2000-10-12 2005-01-13 Linghang Zhuang Aza-and polyaza-naphthalenly ketones useful as hiv integrase inhibitors
AU2002229057B2 (en) * 2000-12-14 2005-04-21 Warner Chilcott Company, Llc Cyclization process step in the making of quinolones and naphthyridines
AU2002305926A1 (en) 2001-02-05 2002-10-08 Exegenics Inc. Cysteine protease inhibitors
KR20030078958A (ko) 2001-03-01 2003-10-08 시오노기세이야쿠가부시키가이샤 Ｈｉｖ 인테그라제 저해 활성을 갖는 질소 함유의헤테로아릴 화합물
JP4518302B2 (ja) 2001-03-19 2010-08-04 日本化薬株式会社 水溶性ジスアゾ化合物、水性ブラックインク組成物および着色体
JP2002293745A (ja) 2001-03-29 2002-10-09 St Marianna Univ School Of Medicine 慢性関節リウマチ治療剤
JP3980842B2 (ja) 2001-05-11 2007-09-26 バブコック日立株式会社 アンモニア含有排水の浄化装置および浄化方法
JP2003065807A (ja) 2001-08-29 2003-03-05 Mitsubishi Electric Corp プロセスデータのトレンド表示方法および装置
JP3913037B2 (ja) 2001-10-30 2007-05-09 三菱電機株式会社 赤外線検出器
TW200300349A (en) 2001-11-19 2003-06-01 Sankyo Co A 4-oxoqinoline derivative
SI1564210T1 (sl) * 2002-11-20 2010-01-29 Japan Tobacco Inc 4-oksokinolinske spojine in njihova uporaba kot inhibitorji HIV integraze
JP2004253231A (ja) 2003-02-20 2004-09-09 Pioneer Electronic Corp プラズマディスプレイパネル
US7531554B2 (en) * 2004-05-20 2009-05-12 Japan Tobacco Inc. 4-oxoquinoline compound and use thereof as HIV integrase inhibitor
MY134672A (en) * 2004-05-20 2007-12-31 Japan Tobacco Inc Stable crystal of 4-oxoquinoline compound
EP2332538A1 (en) * 2004-05-21 2011-06-15 Japan Tobacco, Inc. Combinations comprising a 4-isoquinolone derivative and anti-HIV agents
WO2007102499A1 (ja) 2006-03-06 2007-09-13 Japan Tobacco Inc. ４－オキソキノリン化合物の製造方法
BRPI0708685B8 (pt) 2006-03-06 2021-05-25 Japan Tobacco Inc composto de 4-oxoquinolina, seu uso e método para produção dos mesmos
TW200811153A (en) * 2006-06-23 2008-03-01 Japan Tobacco Inc 6-(heterocyclyl-substituted benzyl)-4-oxoquinoline compound and use thereof as HIV integrase inhibitor
CA2661943C (en) 2006-09-12 2015-11-03 Gilead Sciences, Inc. Process and intermediates for preparing integrase inhibitors
AR068403A1 (es) 2007-09-11 2009-11-18 Gilead Sciences Inc Proceso e intermediarios para la preparacion de inhibidores de integrasa
US7994194B2 (en) * 2007-09-12 2011-08-09 Concert Pharmaceuticals, Inc. 4-oxoquinoline derivatives
CA2711500A1 (en) 2008-01-07 2009-07-16 Huanming Chen Novel hiv integrase inhibitors and methods of use
SI23420A (sl) 2010-07-22 2012-01-31 Institut "Jožef Stefan" Kostni vsadki z večslojno prevleko in postopek njihove priprave
US11347056B2 (en) 2018-08-22 2022-05-31 Microsoft Technology Licensing, Llc Foveated color correction to improve color uniformity of head-mounted displays
US11996736B2 (en) 2018-08-23 2024-05-28 Lg Innotek Co., Ltd. Sensing device
WO2020040561A1 (ko) 2018-08-24 2020-02-27 한온시스템 주식회사 차량용 공조장치

Also Published As

Publication number Publication date
HUS1300066I1 (hu) 2016-11-28
US20230190730A1 (en) 2023-06-22
NO2013015I1 (no) 2013-11-07
LTPA2013018I1 (lt) 2022-09-12
SK2662004A3 (sk) 2005-06-02
US20050239819A1 (en) 2005-10-27
BRPI0306214B1 (pt) 2017-08-08
EP2272516A2 (en) 2011-01-12
CA2470365C (en) 2011-05-17
DE60329318D1 (de) 2009-10-29
IL162548A (en) 2008-12-29
SI1564210T1 (sl) 2010-01-29
BE2013C063I2 (OSRAM) 2023-03-07
AU2003302029B2 (en) 2006-08-10
EP2161258A2 (en) 2010-03-10
US20150174117A1 (en) 2015-06-25
US20060217413A1 (en) 2006-09-28
TW200412339A (en) 2004-07-16
AU2003302029A1 (en) 2004-06-15
DK1564210T5 (da) 2010-05-03
PT1564210E (pt) 2009-10-26
CZ2004764A3 (cs) 2005-02-16
EP2161258A3 (en) 2010-04-07
NO327098B1 (no) 2009-04-20
LU92307I9 (OSRAM) 2019-01-17
NZ533641A (en) 2006-07-28
EP4059923A1 (en) 2022-09-21
US20130172344A1 (en) 2013-07-04
KR20040081443A (ko) 2004-09-21
FR13C0061I1 (OSRAM) 2013-12-20
EP1564210A1 (en) 2005-08-17
US8232401B2 (en) 2012-07-31
PE20040840A1 (es) 2004-12-30
BR0306214A (pt) 2004-08-24
US20200101061A1 (en) 2020-04-02
MY136173A (en) 2008-08-29
CA2470365A1 (en) 2004-06-03
ES2329240T3 (es) 2009-11-24
AR042095A1 (es) 2005-06-08
NO2022032I1 (no) 2022-07-22
NO2013015I2 (no) 2014-06-02
CY1110690T1 (el) 2015-06-10
AU2003302029B8 (en) 2006-08-17
EP3406596A1 (en) 2018-11-28
TR200401663T1 (tr) 2005-04-21
DK1564210T3 (da) 2009-11-16
HK1080852A1 (en) 2006-05-04
EP2272516A3 (en) 2011-03-16
FR13C0061I2 (fr) 2014-11-07
CY2013043I1 (el) 2020-05-29
NO20043004L (no) 2004-07-14
BRPI0306214B8 (OSRAM) 2021-05-25
AR087046A2 (es) 2014-02-12
ATE443048T1 (de) 2009-10-15
EP1564210B1 (en) 2009-09-16
LU92307I2 (fr) 2014-01-13
US7176220B2 (en) 2007-02-13
WO2004046115A1 (ja) 2004-06-03
ZA200404537B (en) 2005-08-31
EP1564210B9 (en) 2010-03-31
IL162548A0 (en) 2005-11-20
KR100665919B1 (ko) 2007-03-08
EP1564210A4 (en) 2007-08-22
TWI248928B (en) 2006-02-11

Similar Documents

Publication Publication Date Title
MXPA04006553A (es) Compuesto de 4-oxoquinolina y uso del mismo como inhibidor de integrasa de vih.
TW200510425A (en) Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor
MY144773A (en) 6-(heterocycle-susbtituted benzyl) -4-oxoquinoline compound and use of the same as hiv integrase inhibitor
MXPA04012965A (es) Inhibidores virales.
BR0315166A (pt) Uso de um composto ou de um sal farmaceuticamente aceitável do mesmo, composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, método para produzir um efeito inibidor de 11betahsd1 em um animal de sangue quente, tal como o homem, que necessita de tratamento
BG100455A (en) Hiv protease inhibitors
DE60036961D1 (de) Gamma-hydroxy-2-(fluoralkylaminocarbonyl)-1-piperazinpentanamide als hiv-proteasehemmer
RU95122135A (ru) Комбинация для профилактики и лечения спида, фармацевтическая композиция на ее основе
TW200603783A (en) Non-nucleoside reverse transcriptase inhibitors
BR9408305A (pt) Composto composição farmacêutica processos para tratamento de aids e da infecção por hiv para preparação da infecção por hiv e para inibição de protease de hiv e combinação de compostos
GR3035014T3 (en) N-(3-amino-2-hydroxybutyl)sulphonamide derivatives as hiv protease inhibitors
ATE386523T1 (de) Synergistische pharmazeutische zusammensetzungen zur behandlung bzw. prophylaxe von diabetes
DE69909747D1 (de) Pharmazeutische zusammensetzung, enthaltend peg-asparaginase, für die behandlung von hiv infektionen
SE0201837D0 (sv) Chemical compounds
WO2003016266A1 (fr) Composes $g(b)-cetoamides et leur utilisation medicinale
WO1996000068A3 (en) Combination therapy for hiv infection
ATE447953T1 (de) Pharmazeutische zusammensetzungen zur behandlung von leishmaniasis
ZA200207586B (en) Diphenyl ketoaldehyde derivatives with anti-HIV activity.
DE60233578D1 (de) Phosphorenthaltende Verbindugnen mit antithrombitische Wirkung
CA2499620A1 (en) External preparation containing acetylsalicylic acid for inhibiting keloid formation
ATE301997T1 (de) Antivirale therapie
UA31078A (uk) Інгібітор вірусу імунодефіциту людини ( даримід )
DK0774969T3 (da) HIV-proteaseinhibitor kombination
ZA929974B (en) Pharmaceutical composition for inhibiting the infection with AIDS virus
AU4485101A (en) Antiviral therapy

Legal Events

Date Code Title Description
FG Grant or registration
GD Licence granted
GD Licence granted